Peng, David H. http://orcid.org/0000-0003-0511-1888
Rodriguez, B. Leticia
Diao, Lixia http://orcid.org/0000-0001-6995-4492
Gaudreau, Pierre-Olivier
Padhye, Aparna http://orcid.org/0000-0001-6169-7372
Konen, Jessica M.
Ochieng, Joshua K. http://orcid.org/0000-0001-5082-3353
Class, Caleb A.
Fradette, Jared J. http://orcid.org/0000-0001-6712-2860
Gibson, Laura http://orcid.org/0000-0003-1668-6898
Chen, Limo
Wang, Jing http://orcid.org/0000-0002-5398-0802
Byers, Lauren A. http://orcid.org/0000-0002-0780-2677
Gibbons, Don. L. http://orcid.org/0000-0003-2362-3094
Article History
Received: 27 May 2020
Accepted: 31 March 2021
First Online: 10 May 2021
Competing interests
: D.L.G. declares advisory board work for Janssen, AstraZeneca, GlaxoSmithKline, and Sanofi. D.L.G. receives research grant funding from AstraZeneca, Janssen, Astellas, Ribon Therapeutics, NGM Therapeutics, and Takeda. L.A.B. declares consulting work for AstraZeneca, AbbVie, GenMab, BergenBio, Pharma Mar, SA. L.A.B. receives research grant funding from AbbVie, AstraZeneca, GenMab, Tolero Pharmaceuticals. All other authors declare that they have no competing interests.